PCLAF and hepatocellular carcinoma: This study demonstrates that CLTB promotes HCC progression through the NF‐κB–PCLAF signaling axis and sEV‐mediated vascular remodeling, providing a mechanistic foundation for developing combination therapies targeting CLTB.